Novo Nordisk A/S (NVO)
Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 68.2827
- Book/Share 31.2062
- PB 15.0315
- Debt/Equity 0.857
- CurrentRatio 0.7386
- ROIC 0.3875
- MktCap 2016834871904.0981
- FreeCF/Share 16.8361
- PFCF 26.9832
- PE 19.906
- Debt/Assets 0.2427
- DivYield 0.0225
- ROE 0.8124
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
| Upgrade | NVO | Kepler | Hold | Buy | -- | -- | March 13, 2025 |
| Downgrade | NVO | Stifel | Buy | Hold | -- | -- | March 3, 2025 |
| Initiation | NVO | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVO | Bernstein | Underperform | Market Perform | -- | -- | Jan. 6, 2025 |
News
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128874&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline – NVO
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128859&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline – NVO
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128830&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
SAN FRANCISCO, CA / ACCESS Newswire / February 11, 2025 / Novo Nordisk A/S (NYSE:NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now.
Read More
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128798&wire=1 or contact Joseph E. Levi, Esq.
Read More
Contact Levi & Korsinsky by March 25, 2025 Deadline to Join Class Action Against Novo Nordisk A/S(NVO)
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128741&wire=1 or contact Joseph E. Levi, Esq.
Read More
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between November 2, 2022 and December 19, 2024.
Read More
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128693&wire=1 or contact Joseph E. Levi, Esq.
Read More
Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128658&wire=1 or contact Joseph E. Levi, Esq.
Read More
Novo Nordisk A/S Class Action: Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 – NVO
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128625&wire=1 or contact Joseph E. Levi, Esq.
Read More
Novo Nordisk A/S Class Action: Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128587&wire=1 or contact Joseph E. Levi, Esq.
Read More
Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128459&wire=1 or contact Joseph E. Levi, Esq.
Read More
Novo Nordisk A/S Class Action: Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128553&wire=1 or contact Joseph E. Levi, Esq.
Read More
Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128524&wire=1 or contact Joseph E. Levi, Esq.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) and certain of its officers.
Read More
Levi & Korsinsky Reminds Novo Nordisk A/S Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128496&wire=1 or contact Joseph E. Levi, Esq.
Read More
NVO CLASS ACTION NEWS: Novo Nordisk has been Sued for Securities Fraud - Contact BFA Law by March 25 if you Suffered Losses
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE:NVO) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Novo Nordisk, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/novo-nordisk-as.
Read More
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
Published: February 10, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Feb. 10, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE: NVO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 02, 2022 and December 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 25, 2025.
Read More
MoneyShow's Best Investment Ideas For 2025: Part 10
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral
MoneyShow's Best Investment Ideas For 2025: Part 10
Read More
Novo Nordisk A/S Class Action: Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128483&wire=1 or contact Joseph E. Levi, Esq.
Read More
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design – Hagens Berman
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now.
Read More
Contact Levi & Korsinsky by March 25, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128444&wire=1 or contact Joseph E. Levi, Esq.
Read More
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Novo Nordisk A/S
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company") (NYSE:NVO) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 02, 2022 and December 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 25, 2025.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Investors Have Opportunity to Lead Class Action Lawsuit!
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period").
Read More
Is Novo Nordisk's Bottom Here? Oversold Status Below 10Y P/E Lows
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk's drastic selloff may be attributed to the management overpromising CagriSema's 25% weight loss target along with the decelerating top-line growth trend. The company now faces numerous headwinds from the Centers for Medicare and Medicaid Services, GLP1 compounders, and new biotech companies. Even so, we believe that the correction has been overly done, with NVO now trading way below its 10Y P/E means and its direct competitors.
Read More
Contact Levi & Korsinsky by March 25, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128404&wire=1 or contact Joseph E. Levi, Esq.
Read More
The Gross Law Firm Reminds Novo Nordisk A/S Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
Published: February 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 09, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $NVO #NVO--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordis.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Mr. Lars Fruergaard Jorgensen
- Employees 77406